(Reuters) - Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits. The Chicago, Illinois-based company sells genomic diagnostics tests across oncology and other areas, including neuropsychiatry, radiology and cardiology to clinicians and hospital systems. Seven brokerages, including J.P.Morgan, Morgan Stanley, BofA Global Research and Stifel initiated coverage with a "buy" or "overweight" rating, with the highest price target of $50 by TD Cowen. The brokerages, which were underwriters for Tempus' initial public offering, issued their first ratings after the so-called "quiet period" ended on Tuesday. The upbeat ratings lifted the shares of the company by 6.9% to $35.57. The stock has lost 17.5% since the closing on June 14, its debut day, till the end of trade on Monday. J.P.Morgan forecasts roughly 33% revenue growth for Tempus through 2027. It expects the company to turn a core profit by the second half of 2025. Tempus AI's net loss widened to $289.8 million in 2023 from $214.1 million a year earlier, while total revenue jumped 65.8% to $531.8 million. The "uniquely combined clinical genomic data, which the company has successfully monetized in the form of licensing agreements with pharma and biotech customers" separates Tempus from rivals, according to J.P.Morgan. Morgan Stanley expects revenue growth of 27% through 2028, and expects the company to break-even on core profit by 2027. The brokerage noted that if competitors tried to grow their own database, it would "likely prove to be costly, cumbersome and time-consuming efforts". BofA Global Research said there is space for Tempus to further expand the scope of the existing relationships with biotech and large pharma companies as well as increase the number of new customers. (Reporting by Roshan Abraham in Bengaluru; Editing by Shilpi Majumdar)
Wall Street analysts bullish on genetic testing firm Tempus AI
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...